Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab

Am J Hematol. 2009 Jun;84(6):387-8. doi: 10.1002/ajh.21415.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Doxycycline / administration & dosage
  • Doxycycline / pharmacology*
  • Humans
  • Immunohistochemistry
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Mice
  • Mice, SCID
  • Rituximab
  • Xenograft Model Antitumor Assays

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Rituximab
  • Doxycycline